Platelet-bioengineered hiPSC-sEVs achieve targeted repair of fibrotic sinoatrial node in preclinical SND models
Quick Facts
- Publication title: Platelet-bioengineered hiPSC-sEVs achieve targeted repair of fibrotic sinoatrial node in preclinical SND models
- Journal: Nat Commun
- Year: 2025
- DOI: 10.1038/s41467-025-65936-0
- PMID/PMCID: 41365863; PMC12689679
Research overview
This study establishes a targeted, cell-free nanotherapeutic platform for resolving fibrosis and electrophysiological dysfunction in sinus node disease. Small extracellular vesicles derived from human induced pluripotent stem cells possess regenerative potential but lack targeted delivery.
Key findings
Sinus node dysfunction, a prevalent arrhythmia in aging populations, is characterized by fibrosis and loss of pacemaker activity, necessitating pacemaker implantation.
Current therapies fail to reverse the underlying pathology.
Small extracellular vesicles derived from human induced pluripotent stem cells possess regenerative potential but lack targeted delivery.
Here, we engineer platelet membrane-fused vesicles that synergistically combine collagen targeting for ischemic injury homing with immune evasion.
Echo Biotech Role
Echo Biotech contributed EV isolation and purification; the study also used or cited Exosupur®.
Related platforms: Exoomics®, Research Reagents & Tools
Related services and capabilities: Cell-Culture Supernatant EV Isolation & Purification, Research Reagent / Product Supply
Related products or reagents: Exosupur® EV Isolation/Purification Kit
References
Original publication: Platelet-bioengineered hiPSC-sEVs achieve targeted repair of fibrotic sinoatrial node in preclinical SND models Nature communications. 2025. DOI: 10.1038/s41467-025-65936-0. PMID/PMCID: 41365863; PMC12689679.